Showing posts with label Fierce Biotech. Show all posts
Showing posts with label Fierce Biotech. Show all posts
[SOURCE: Fierce Biotech] This month three Canaccord Adams analysts--Adam Cutler, George Farmer and Ritu Baral (bios and photos)--weigh in on five developers that are facing pivotal events. A timely regulatory approval would mean a lot for one of these companies, another is pushing a new cancer therapy into crucial late-stage trials and a third is fishing for a potential partnership that could make a big difference as it advances three programs in the clinic. A well-timed NDA filing could set the stage for another pact while our fifth company faces a near-term decision from the FDA and some big decisions on a possible partner. Featured in this issue of On the Radar are Cadence Pharmaceuticals, Micromet, Momenta Pharmaceuticals, Pharmasset, and Protalix BioTherapeutics.
Read more @ Fierce Biotech
Complete Genomics publishes in Science on low-cost sequencing of 3 human genomes
MOUNTAIN VIEW, Calif. - Nov. 5, 2009 - Complete Genomics, a third-generation human genome sequencing company, today announced publication of a report in the journal Science describing its proprietary DNA sequencing platform, including analysis of sequence data from three complete human genomes. The consumables cost for these three genomes sequenced on the proof-of-principle genomic DNA nanoarrays ranged from $8,005 for 87x coverage to $1,726 for 45x coverage for the samples described in this report.
The 2009 Biotech Graveyard - FierceBiotech
Last year National Venture Capital Association President Mark Heesen predicted that the coming financial crisis would make or break many small developers. The strong would survive, and the weak would not have what it took to raise cash during the credit crunch. Below is that unfortunate bunch; 16 notable companies that didn't have the money, expertise or programs to live to see another day.
Subscribe to:
Posts (Atom)